TLR9 and pancreatic neoplasm: Along with targeting cell surface TAAs, ER intrabodies targeting membrane proteins in intracellular compartments have also been developed, such as intrabodies against toll-like receptor 9 (TLR9), which diminishes the development of pancreatic tumor [69].